Study details
Enrolling now
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
NCT IDNCT06533579ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
32
Study length
about 6.3 years
Ages
13–90
Locations
9 sites in CA, CO, NC +5
About this study
This trial is testing a treatment called VNX-101 in people with relapsed or refractory CD19-positive blood cancers. The goal is to see if VNX-101 is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dose Level 1, VNX-101
- 2.Take Dose Level 2, VNX-101
- 3.Take Dose Level 3, VNX-101
- +1 more
PhasePhase 1/Phase 2
Primary goalTreatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)
Secondary: Change from baseline in B-cell counts, Proportion/duration of subjects achieving response, progression free survival, and disease free survival.
Body systems
Oncology